FDA Approves LIALDA (mesalamine), The First Oral Once-Daily Mesalamine For Patients With Active, Mild To Moderate Ulcerative Colitis

... Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has approved LIALDATM (mesalamine) with MMX(R) technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine. [click link for full article] ...